Annotation Detail
Information
- Associated Genes
- MYC
- Associated Variants
-
MYC OVEREXPRESSION
MYC OVEREXPRESSION - Associated Disease
- lung small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- A preclinical study to evaluate the efficacy of targeting the overexpressed CHEK1 cell cycle chekpoint kinase, including both miRNA and Prexasertib-induced inhibition. Both in vitro and in vivo, Prexasertib had strong single agent efficacy and augmented the effect of Olaparib or Cisplatin in either combination, including platinum-resistant models. CHEK1 and MYC overexpression were predictors of response.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3003
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3737
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1303
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Prexasertib,Cisplatin,Olaparib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 28490518
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cisplatin | Sensitivity | true |
| Olaparib | Sensitivity | true |
| Prexasertib | Sensitivity | true |